Jordan Wilkins1, Dhananjay Sakrikar2, Xuan-Mai Petterson2, Ian R Lanza2,3, Eugenia Trushina4,5. 1. Department of Neurology, Mayo Clinic, Rochester, MN, 55905, USA. 2. Metabolomics Core Laboratory, Mayo Clinic, Rochester, MN, 55905, USA. 3. Division of Endocrinology, Mayo Clinic, Rochester, MN, 55905, USA. 4. Department of Neurology, Mayo Clinic, Rochester, MN, 55905, USA. trushina.eugenia@mayo.edu. 5. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Guggenheim Bld., Room 1542B, Rochester, MN, 55905, USA. trushina.eugenia@mayo.edu.
Abstract
INTRODUCTION: Patient-derived skin fibroblasts offer a unique translational model to study molecular mechanisms of multiple human diseases. Metabolomics profiling allows to track changes in a broad range of metabolites and interconnected metabolic pathways that could inform on molecular mechanisms involved in disease development and progression, and on the efficacy of therapeutic interventions. Therefore, it is important to establish standardized protocols for metabolomics analysis in human skin fibroblasts for rigorous and reliable metabolic assessment. OBJECTIVES: We aimed to develop an optimized protocol for concurrent measure of the concentration of amino acids, acylcarnitines, and components of the tricarboxylic acid (TCA) cycle in human skin fibroblasts using gas (GC) and liquid chromatography (LC) coupled with mass spectrometry (MS). METHODS: The suitability of four different methods of cell harvesting on the recovery of amino acids, acylcarnitines, and TCA cycle metabolites was established using GC/MS and LC/MS analytical platforms. For each method, metabolite stability was determined after 48 h, 2 weeks and 1 month of storage at - 80 °C. RESULTS: Harvesting cells in 80% methanol solution allowed the best recovery and preservation of metabolites. Storage of samples in 80% methanol up to 1 month at - 80 °C did not significantly impact metabolite concentrations. CONCLUSION: We developed a robust workflow for metabolomics analysis in human skin fibroblasts suitable for a high-throughput multiplatform analysis. This method allows a direct side-by-side comparison of metabolic changes in samples collected at different time that could be used for studies in large patient cohorts.
INTRODUCTION:Patient-derived skin fibroblasts offer a unique translational model to study molecular mechanisms of multiple human diseases. Metabolomics profiling allows to track changes in a broad range of metabolites and interconnected metabolic pathways that could inform on molecular mechanisms involved in disease development and progression, and on the efficacy of therapeutic interventions. Therefore, it is important to establish standardized protocols for metabolomics analysis in human skin fibroblasts for rigorous and reliable metabolic assessment. OBJECTIVES: We aimed to develop an optimized protocol for concurrent measure of the concentration of amino acids, acylcarnitines, and components of the tricarboxylic acid (TCA) cycle in human skin fibroblasts using gas (GC) and liquid chromatography (LC) coupled with mass spectrometry (MS). METHODS: The suitability of four different methods of cell harvesting on the recovery of amino acids, acylcarnitines, and TCA cycle metabolites was established using GC/MS and LC/MS analytical platforms. For each method, metabolite stability was determined after 48 h, 2 weeks and 1 month of storage at - 80 °C. RESULTS: Harvesting cells in 80% methanol solution allowed the best recovery and preservation of metabolites. Storage of samples in 80% methanol up to 1 month at - 80 °C did not significantly impact metabolite concentrations. CONCLUSION: We developed a robust workflow for metabolomics analysis in human skin fibroblasts suitable for a high-throughput multiplatform analysis. This method allows a direct side-by-side comparison of metabolic changes in samples collected at different time that could be used for studies in large patient cohorts.
Authors: Jon B Toledo; Matthias Arnold; Gabi Kastenmüller; Rui Chang; Rebecca A Baillie; Xianlin Han; Madhav Thambisetty; Jessica D Tenenbaum; Karsten Suhre; J Will Thompson; Lisa St John-Williams; Siamak MahmoudianDehkordi; Daniel M Rotroff; John R Jack; Alison Motsinger-Reif; Shannon L Risacher; Colette Blach; Joseph E Lucas; Tyler Massaro; Gregory Louie; Hongjie Zhu; Guido Dallmann; Kristaps Klavins; Therese Koal; Sungeun Kim; Kwangsik Nho; Li Shen; Ramon Casanova; Sudhir Varma; Cristina Legido-Quigley; M Arthur Moseley; Kuixi Zhu; Marc Y R Henrion; Sven J van der Lee; Amy C Harms; Ayse Demirkan; Thomas Hankemeier; Cornelia M van Duijn; John Q Trojanowski; Leslie M Shaw; Andrew J Saykin; Michael W Weiner; P Murali Doraiswamy; Rima Kaddurah-Daouk Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 16.655
Authors: María J Pérez; Daniela P Ponce; Cesar Osorio-Fuentealba; Maria I Behrens; Rodrigo A Quintanilla Journal: Front Neurosci Date: 2017-10-06 Impact factor: 4.677
Authors: Sidney Behringer; Victoria Wingert; Victor Oria; Anke Schumann; Sarah Grünert; Artur Cieslar-Pobuda; Stefan Kölker; Ann-Kathrin Lederer; Donald W Jacobsen; Judith Staerk; Oliver Schilling; Ute Spiekerkoetter; Luciana Hannibal Journal: Metabolites Date: 2019-10-18